Cell membrane phospholipid remodeling enzyme LPCAT3 emerges as a metabolic target driving acute myeloid leukemia progression
Background
Acute myeloid leukemia (AML) is a fatal malignancy where immature myeloid progenitors proliferate abnormally, paralyzing normal hematopoietic functions. Due to varying genetic mutations and molecular biological characteristics among patients, high recurrence rates and resistance frequently occur even with conventional chemotherapy or targeted therapies. The oncology community is focusing on the disruption of cellular homeostasis that sustains cancer cell division and survival. Proliferating leukemia cells appear to actively remodel lipid metabolism to maintain physical membrane structures and transmit growth signals.
The Lands' cycle, a remodeling pathway for phospholipids—key lipids in the cell membrane—is an essential biochemical process regulating membrane fluidity and cellular functions. However, it has not been clearly elucidated how metabolic enzymes involved in the Lands' cycle specifically act on AML progression and leukemia cell viability. As existing targeted therapy strategies encounter acquired resistance, there is an urgent need to identify fundamental vulnerabilities in leukemia cell membrane metabolism.
Key Findings
Researchers have identified lysophosphatidylcholine acyltransferase 3 (LPCAT3), a key enzyme in the Lands' cycle, as a major factor driving the malignant progression of AML. Analysis of large-scale public transcriptomic data and patient-derived CD34-positive (CD34+) cells revealed that LPCAT3 expression levels are significantly elevated in patient tissues compared to normal cell groups. It was confirmed that patient groups with high LPCAT3 expression levels have significantly poorer overall survival than those with low levels.
Similar trends were captured in experiments using representative AML models, the MOLM-13 and THP-1 cell lines. Inhibiting LPCAT3 using gene silencing via short hairpin RNA (shRNA) and CRISPR-Cas9 knockout technology resulted in slowed cell proliferation. Cell cycle analysis showed induced G0/G1 phase arrest, and the rate of apoptosis significantly increased. Xenograft mouse models injected with LPCAT3-deficient cells also showed a noticeably reduced leukemic burden in vivo compared to the control group.
RNA sequencing (RNA-seq) analysis provided crucial clues for identifying the detailed mechanism. In cells where LPCAT3 was inhibited, differentially expressed genes (DEGs) were concentrated in pathways related to granulocyte chemotaxis. This implies that the loss of metabolic enzymes changed the transcriptomic landscape in a direction that relieves the inhibition of leukemia cell differentiation and normalizes interactions with the microenvironment.
Significance and Outlook
This study is significant in that it proves LPCAT3, a cell membrane lipid metabolism enzyme, as a new target for AML, moving beyond the gene mutation-centered approach. It demonstrates the effectiveness of a metabolic therapeutic approach that disrupts the physical stability of cancer cells by manipulating cell membrane phospholipid composition. Follow-up studies investigating the connection with the regulation of polyunsaturated fatty acid oxidation or ferroptosis (iron-dependent cell death) are also expected to gain momentum.
Challenges remain for actual clinical application. LPCAT3 is considered an essential enzyme involved in lipid absorption and lipoprotein synthesis in normal organs as well. It is pointed out that the risk of toxicity to normal cells and metabolic imbalance during systemic administration cannot be ruled out. Establishing a delivery system that precisely targets only leukemia cells while protecting normal hematopoietic stem cells is an essential task. Furthermore, analysis suggests that the discovery of clinical-grade small molecule compounds that selectively inhibit LPCAT3 must accompany this effort.
Acute myeloid leukemia (AML) is a group of genetically and clinically heterogeneous malignancies characterized by clonal expansion of immature myeloid progenitors and profound disruption of normal hematopoiesis. Emerging evidence suggests that alterations in cellular homeostasis shape cancer progression. However, the mechanisms underlying AML progression remain largely unclear. Here, we identify lysophosphatidylcholine acyltransferase 3 (LPCAT3), a key enzyme of the Lands' cycle, as a critical regulator of AML progression. Analysis of public transcriptomic datasets and patient-derived CD34+ cells
The LPCAT3 targeting strategy may offer an alternative for the treatment of refractory AML patients who exhibit resistance to existing standard anticancer therapies. A representative scenario is designing a treatment protocol that co-administers LPCAT3 inhibitors to overcome secondary resistance appearing after the administration of FLT3 or IDH1/2 inhibitors. Another valid strategy is a combination therapy aimed at increasing the intracellular penetration efficiency of existing anticancer drugs or seeking synergistic effects with apoptosis inducers by artificially destabilizing the lipid composition of leukemia cell membranes. The LPCAT3 expression level confirmed in patient-derived CD34-positive cells is expected to be introduced into clinical practice as a companion diagnostic biomarker to assess a patient's initial risk group and treatment responsiveness.